In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Marina Vilar Geraldi *Sahlgrenska Osteoporosis Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-2814-8424 Chinmay Dwibedi *The Wallenberg Laboratory, Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0001-6416-4440 Raju JaiswalSahlgrenska Osteoporosis Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0001-6533-0455 Giulia GregoriSahlgrenska Osteoporosis Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
Xiaofeng ZhouState Key Laboratory of Genetic and Development of Complex Phenotypes, Human Phenome Institute, and Fudan Microbiome Center, School of Life Sciences, Fudan University, Shanghai, China.
Bomin LvState Key Laboratory of Genetic and Development of Complex Phenotypes, Human Phenome Institute, and Fudan Microbiome Center, School of Life Sciences, Fudan University, Shanghai, China.
Yan ZhengState Key Laboratory of Genetic and Development of Complex Phenotypes, Human Phenome Institute, and Fudan Microbiome Center, School of Life Sciences, Fudan University, Shanghai, China.ORCID 0000-0003-1129-3147 Xiaofeng WangState Key Laboratory of Genetic and Development of Complex Phenotypes, Human Phenome Institute, and Fudan Microbiome Center, School of Life Sciences, Fudan University, Shanghai, China.
Hao WuState Key Laboratory of Genetic and Development of Complex Phenotypes, Human Phenome Institute, and Fudan Microbiome Center, School of Life Sciences, Fudan University, Shanghai, China.ORCID 0000-0003-1314-4954 Kristian F AxelssonSahlgrenska Osteoporosis Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-4118-6038 Fredrik BäckhedThe Wallenberg Laboratory, Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
Valentina TremaroliThe Wallenberg Laboratory, Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-9150-4233 Mattias LorentzonSahlgrenska Osteoporosis Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden. mattias.lorentzon@medic.gu.se.ORCID 0000-0003-0749-1431 Funding
Familjen Erling-Perssons Stiftelse (Erling-Persson Family Foundation) 2024-0104IngaBritt och Arne Lundbergs Forskningsstiftelse (Ingabritt and Arne Lundberg Research Foundation) Lorentzon, 2016Knut och Alice Wallenbergs Stiftelse (Knut and Alice Wallenberg Foundation) KAW 2020.0239Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (King Gustaf V and Queen Victoria's Foundation of Freemasons) Lorentzon, 2023-2024Vetenskapsrådet (Swedish Research Council) 2023-01976, 2023-01976, 2022-06725, 2018-05973, 2024-03723,
6 · The paper itselfAbstract
Frailty is a multifactorial geriatric condition linked to increased mortality and adverse health outcomes and is associated with gut microbiome features that differ from those observed in healthy ageing. We analyze gut metagenomic profiles in relation to estimated frailty severity and frailty-related clinical outcomes assessed with an internally developed and validated Frailty Mortality Index (FMI) in the SUPERB cohort, comprising 2,081 Swedish women aged 75-80 years. The FMI is a composite measure that integrates functional, physiological and psychological dimensions associated with frailty and mortality risk, and shows stronger associations with mortality compared to the Charlson Comorbidity Index in the SUPERB cohort. The FMI is inversely associated with microbial diversity, gene richness, and predicted functional capacity, which are linked to physical function, mortality and fall-related injuries. A total of 404 bacterial species are significantly associated with FMI, and most show concordant associations in a Chinese cohort of 1,448 older adults. Here we show microbial signatures linked to frailty and mortality across different continents.
Indexed as
FrailtyGastrointestinal MicrobiomeAgedAged, 80 and overBacteriaCohort StudiesFemaleFrail ElderlyHumansSweden
Identifiers
PMID42420265
PMCPMC13346421
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390